Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Can Higher Networking Revenues Aid Ciena (CIEN) Q2 Earnings?

Published 05/28/2018, 08:55 AM
Updated 07/09/2023, 06:31 AM

Ciena Corporation (NYSE:CIEN) is scheduled to report second-quarter fiscal 2018 financial results (ending Apr 28, 2018) before the opening bell on May 31. The company is likely to report higher consolidated revenues led by healthy growth dynamics.

Whether this could result into an earnings beat remains to be seen.

Factors to Consider

During the quarter, Ciena’s GeoMesh solution was selected by Sweden-based Eastern Light to help meet the region’s fast-growing demand for long-haul dark fiber. The company also unveiled 5G network solutions to help operators expand their 4G networks and prepare for 5G.

Ciena’s 6500 packet-optical platform was deployed by U.K.-based Jisc to provide Janet Network, the first National Research and Education Network, with high-capacity 400G wavelength connectivity.

In the fiscal second quarter, the company added an important aggregation, scale and programmability capability. The company’s new 8180 and 6500 Reconfigurable Line System platforms helped to tackle network complexity by combining massive bandwidth scalability and aggregation with integrated intelligence and programmability to improve end-user experience.

Furthermore, in the quarter, Ciena introduced an enhanced policy capability into its Blue Planet intelligent automation platform that incorporates the architectural framework from the Linux Foundation’s open-source Open Networking Automation Platform to aid network providers’ evolution to more adaptive, software-centric networks.

The Zacks Consensus Estimate for total revenues for the Networking Platforms segment, which accounts for the lion’s share of total revenues, is currently pegged at $574 million, up from $572 million reported in second-quarter fiscal 2017. Revenues from Global Network Service segment are expected to be $103 million compared with $98 million reported in the prior-year quarter. Revenues from Software and Services are estimated to be $49.7 million compared with $37.7 million reported in the year-ago quarter. Consequently, Ciena’s consolidated revenues for the quarter are likely to be $730 million, up from $707 million reported in the year-earlier quarter.

What Our Model Says

Our proven model does not conclusively show that Ciena is likely to beat earnings this quarter as it does not possess one of the two key components. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here as you will see below:

Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -0.19%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Ciena Corporation Price and EPS Surprise

Ciena Corporation Price and EPS Surprise | Ciena Corporation Quote

Zacks Rank: Ciena has a Zacks Rank #3, which when combined with a negative ESP, makes surprise prediction difficult.

Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing a negative estimate revisions momentum.

Stocks to Consider

Here are some companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter:

Herc Holdings Inc. (NYSE:HRI) has an Earnings ESP of +100.00% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Hecla Mining Company (NYSE:HL) has an Earnings ESP of +49.99% and a Zacks Rank #2.

Safe Bulkers, Inc. (NYSE:SB) has an Earnings ESP of +50.00% and a Zacks Rank #2.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



Herc Holdings Inc. (HRI): Free Stock Analysis Report

Safe Bulkers, Inc (SB): Free Stock Analysis Report

Ciena Corporation (CIEN): Free Stock Analysis Report

Hecla Mining Company (HL): Free Stock Analysis Report

Original post
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.